MX2021008009A - Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico. - Google Patents

Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico.

Info

Publication number
MX2021008009A
MX2021008009A MX2021008009A MX2021008009A MX2021008009A MX 2021008009 A MX2021008009 A MX 2021008009A MX 2021008009 A MX2021008009 A MX 2021008009A MX 2021008009 A MX2021008009 A MX 2021008009A MX 2021008009 A MX2021008009 A MX 2021008009A
Authority
MX
Mexico
Prior art keywords
myelodysplastic syndrome
alk5 inhibitors
treating myelodysplastic
alk5
treating
Prior art date
Application number
MX2021008009A
Other languages
English (en)
Inventor
Steven L Warner
David J Bearss
Original Assignee
Sumitomo Pharma Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Oncology Inc filed Critical Sumitomo Pharma Oncology Inc
Publication of MX2021008009A publication Critical patent/MX2021008009A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

En este documento se describen métodos para tratar una enfermedad mediada por ALK5 que incluye síndrome mielodisplásico (MDS), anemia y anemia de enfermedad crónica. También se proporcionan métodos para inhibir la ALK5.
MX2021008009A 2019-01-10 2020-01-10 Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico. MX2021008009A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962790961P 2019-01-10 2019-01-10
PCT/US2020/013214 WO2020146819A1 (en) 2019-01-10 2020-01-10 Alk5 inhibitors for treating myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
MX2021008009A true MX2021008009A (es) 2021-08-05

Family

ID=71520899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008009A MX2021008009A (es) 2019-01-10 2020-01-10 Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico.

Country Status (9)

Country Link
US (2) US20200323851A1 (es)
EP (1) EP3908575A4 (es)
JP (1) JP2022517951A (es)
KR (1) KR20210113314A (es)
CN (1) CN113272281A (es)
AU (1) AU2020207391A1 (es)
CA (1) CA3124714A1 (es)
MX (1) MX2021008009A (es)
WO (1) WO2020146819A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2249831A2 (en) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
MX2013006261A (es) * 2010-12-03 2013-10-01 Ym Biosciences Australia Pty Tratamiento de condiciones mediadas por jak2.
EP2731949B1 (en) * 2011-07-13 2018-04-04 TiumBio Co., Ltd. 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
KR102334260B1 (ko) * 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
TWI582083B (zh) * 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
KR20210038906A (ko) * 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제

Also Published As

Publication number Publication date
JP2022517951A (ja) 2022-03-11
EP3908575A4 (en) 2022-09-14
CA3124714A1 (en) 2020-07-16
US20240075033A1 (en) 2024-03-07
CN113272281A (zh) 2021-08-17
WO2020146819A1 (en) 2020-07-16
US20200323851A1 (en) 2020-10-15
EP3908575A1 (en) 2021-11-17
AU2020207391A1 (en) 2021-06-24
KR20210113314A (ko) 2021-09-15

Similar Documents

Publication Publication Date Title
SA519410622B1 (ar) مثبطات kras g12c و طرق لاستخدامها
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
EA201890428A1 (ru) Ингибиторы контрольных точек иммунного ответа для применения в лечении различных видов рака крови
MX2020002502A (es) Inhibidores de kras g12c y metodos para utilizarlos.
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
MX2018000216A (es) Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos.
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
PH12017501879A1 (en) Methods for treating cancer
MX2021006731A (es) Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
EA201790838A1 (ru) Ингибитор киназы aurora a
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
BR112017023225A2 (pt) inibidor de proteína cinase
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
PH12017501880A1 (en) Methods for treating cancer
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
MX2018003301A (es) Inhibidores de pcna.
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
MX2021008009A (es) Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico.
MX2017013358A (es) Métodos para tratar el cáncer.
IL288953A (en) Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors
EA202191567A1 (ru) Ингибиторы alk5
EP3784240C0 (en) WNT6 AS A GLIOBASTOMA TUMOR MARKER, AND USE OF INHIBITORS THEREOF FOR THE TREATMENT OF WNT6 OVEREXPRESSING GLIOBLASTOMA